AD_____

Award Number: DAMD17-02-1-0338

TITLE: Prostasin Serine Protease as a Breast Cancer Invasion Marker and a Metastasis Suppressor

PRINCIPAL INVESTIGATOR: Karl X. Chai, Ph.D.
                                          Li-Mei Chen, M.D., Ph.D.
                                          Ying Zhang, Ph.D.

CONTRACTING ORGANIZATION: University of Central Florida
                                                    Orlando, FL 32816

REPORT DATE: November 2006

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
                          Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                                          Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE 01-11-2006	2. REPORT TYPE Final	3. DATES COVERED 8 Apr 2002 – 7 Oct 2006

4. TITLE AND SUBTITLE

Prostasin Serine Protease as a Breast Cancer Invasion Marker and a Metastasis Suppressor

5a. CONTRACT NUMBER

5b. GRANT NUMBER
DAMD17-02-1-0338

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Karl X. Chai, Ph.D.

Li-Mei Chen, M.D., Ph.D.
Ying Zhang, Ph.D.

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Central Florida
Orlando, FL 32816

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES
Original contains colored plates: ALL DTIC reproductions will be in black and white.

14. ABSTRACT

This project had one Specific Aim after the peer and programmatic reviews, to evaluate prostasin, a glycosylphosphatidylinositol (GPI)-anchored extracellular serine protease as a potential metastasis suppressor of breast cancer in nude mice models. Two types of breast cancer metastasis, experimental and spontaneous, were to be used with the cell lines MDA-MB-231 and MDA-MB-435, respectively. We have found that prostasin must be activated by another membrane serine protease, matriptase before becoming functionally active as a proteolytic enzyme. The activating enzyme matriptase, however, is not expressed by either of the two model cell lines, an essential factor previously unrecognized, as well as an underlying reason for our previous inconsistent findings concerning prostasin's impact on breast cancer cell metastasis. In future research on membrane serine proteases in breast cancer cell biology, the newly recognized proteolytic cascade should be addressed with consideration of all of its current and potentially new member proteases.

15. SUBJECT TERMS
Invasion/Metastasis, Animal model, Prostasin, Serine protease

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U	UU	13	19b. TELEPHONE NUMBER *(include area code)*

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

Table of Contents

INTRODUCTION:

This project had one Specific Aim after the peer and programmatic reviews, to evaluate prostasin, a glycosylphosphatidylinositol (GPI)-anchored extracellular serine protease as a potential metastasis suppressor of breast cancer in nude mice models. Two types of breast cancer metastasis, experimental and spontaneous, were to be used with the cell lines MDA-MB-231 and MDA-MB-435, respectively. Both of these cell lines were shown not to express prostasin due to promoter DNA hypermethylation, and re-expression of prostasin was associated with a reduced invasion through the Matrigel for both of these cell lines (1). Sublines of the MDA-MB-231 and MDA-MB-435 cell lines expressing prostasin from a human prostasin cDNA were to be injected into the tail vein (for experimental metastasis) and the mammary fat pad (for spontaneous metastasis) and the metastasis incidents were to be scored and compared against vector plasmid-treated control cells.

BODY:

The first technical objective of the project was to validate the expression of human prostasin in the MDA-MB-231 and MDA-MB-435 sublines established from cells of MD Anderson Cancer Center. Expression of the prostasin protein was detected by western blotting as well as immunocytochemistry (previously reported in 2003). The MDA-MB-231 cells expressing prostasin were immediately used for tail vein injection assays, however, mixed results were obtained. Two rounds of animal experiments were performed. In the first round, there was a statistical difference of metastasis loci in animals receiving the MDA-MB-231/Pro cells (expressing prostasin) *versus* those receiving the MDA-MB-231/Vec cells (vector treated control), by analysis of variance (ANOVA). Prostasin re-expression was associated with a reduction of metastasis. These results were reported in 2003. In the second round of experiments, however, no difference in metastasis incidents were observed between mice receiving MDA-MB-231/Pro versus MDA-MB-231/Vec. As we investigated the reasons for such inconsistency in results, we found that the episomally expressed human prostasin cDNA was silenced in the MDA-MB-231/Pro cells, probably from DNA methylation of the viral promoter driving the cDNA expression as previously observed by others (2). This phenotype is likely a result of selective advantage for subpopulation of cells that gradually lost prostasin expression.

To overcome this obstacle in maintaining stable prostasin expression in the experimental cell line models, we employed a tet-on regulated expression system known as the Flp-In T-REx (Invitrogen, Carlsbad, CA). Using this system, a stable subline of MDA-MB-231 cells expressing prostasin when induced with tetracycline (tet), FT-231-15/Pro and the appropriate controls, were established. We confirmed for a near 100% expression by all cells when tet-induction was performed (reported in 2004). These cells along with the proper controls were then used for a new round of tail vein injection in nude mice, which were fed with doxycycline-supplemented water (a tetracycline derivative with longer half-life) for induction of prostasin expression *in vivo*. The tumor metastasis incidents displayed by these sublines, however, were significantly lower than the parent cell line's (MDA-MB-231), effectively prohibiting an accurate evaluation of prostasin's potential role in suppressing metastasis. We considered the reasons for this low rate of tumor metastasis and concluded that the use of doxycycline (a tetracycline derivative) may have suppressed tumor take and growth for both the control and the prostasin-expressing cells, as tetracycline type drugs were previously shown to be suppressive of breast cancer growth and invasion (3). These findings were reported in 2005.

Upon revisiting the prostasin-expressing sublines derived immediately from the parent cells, the MDA-MB-231/Pro for possibilities of using freshly transfected cells for injection, we had made a significant discovery regarding prostasin's biological function. The prostasin serine

4

protease is present on the cell surface as an inactive form, and needs to be activated by another extracellular membrane serine protease, matriptase before any proteolytically relevant functions of prostasin can be performed (4). This finding was made in mice in collaboration with another laboratory (4), but its general relevance in cultured cells was also confirmed (Figure 1). For this experiment, active secreted prostasin (sPro) from cell culture medium and membrane-bound prostasin (MT-Pro) were purified using aprotinin-affinity chromatography as previously described (5). Protease nexin-1 (PN-1) was purified from mouse seminal vesicle (6). Purified matriptase was a gift from our collaborator. The purified proteins were incubated in various mixtures as indicated in Figure 1, at 37°C for 1 hour before western blot analysis was performed on these samples using a rabbit anti-prostasin antibody (5). This assay can distinguish active *versus* inactive serine protease, because only the active protease will interact with its cognate serpin-class inhibitor, *i.e.*, a suicide substrate (5). As shown in Figure 1, the pre-activation membrane-bound prostasin does not form a complex with its cognate serpin-class inhibitor/suicide substrate, PN-1 (Lane 2), indicating a lack of serine protease activity for this form of prostasin. When the membrane-bound prostasin was pre-incubated with matriptase (Mat), a portion of the prostasin became active (*i.e.*, proteolytically activated by matriptase), and formed a complex with PN-1 (Lane 3). The secreted prostasin (sPro) (Lane 1) was run as an active serine protease control (5).

Legend to Figure 1 (right): Purified secreted prostasin (sPro) and membrane prostasin (MT-Pro) were tested for serine protease activity by a PN-1 binding assay as previously described (5). Lane 1, the secreted, active form of prostasin. Lane 2, membrane prostasin. Lane 3, MT-Pro was pre-incubated with matriptase (Mat). Purified mouse PN-1(mPN-1) (6) was added to all binding reactions. This western blot was performed with a rabbit anti-prostasin antibody (5).

Matriptase is synthesized as a type-II transmembrane serine protease with its C-terminal serine protease domain on the outside of the cell (7). Matriptase is autoactivated and is shed off from the cell surface in a complex with its physiological inhibitor, HAI-1. Matriptase is strictly an epithelial serine protease with a broad spectrum of tissue distribution, and has been reported to be over-expressed in various epithelial cancers, including that of the breast (7). There is conflicting information regarding the usefulness of using matriptase expression as a predictor for breast cancer survival. It has been shown that low-invasive human breast cancer cell lines (*e.g.*, MCF-7) and immortalized "normal" human breast epithelial cells (*e.g.*, MCF-10A) express an abundance of matriptase at the protein level, while invasive human breast cancer cell lines such as the MDA-MB-231 and the MDA-MB-435 do no express this serine protease (8).

This new finding concerning prostasin's cell physiologic role complicates the original plans for the current project, because neither of the model cell lines, MDA-MB-231 or MDA-MB-435, expresses the prostasin-activating enzyme matriptase. Taking this important factor into consideration, the results of the first two rounds of tail vein injection should be regarded as incidental changes or differences between the experimental and the control groups. The anti-invasion effect of prostasin expressed in these same cell lines observed previously (1) might be activated by matriptase in the invasion barrier, Matrigel, which may be a rich source of the shed-off version of this protease, also shown to be capable of activating prostasin (Figure 1). When

MDA-MB-231/Pro cells were injected into the tail vein, there is no immediate source for matriptase to complete the mechanism of prostasin activation, leaving the cells expressing prostasin essentially functionally equivalent to those not expressing prostasin.

It has now become clear that the project's goal can only be realized if the model cell lines are co-transfected with prostasin and matriptase, as these two extracellular serine proteases are functioning in an activation cascade to regulate epithelial cell responses, *e.g.*, to cytokines and growth factors (9).

KEY RESEARCH ACCOMPLISHMENTS:

- The extracellular membrane serine protease matriptase activates the GPI-anchored extracellular serine protease prostasin by a proteolytic cleavage. For future research investigating the function of either prostasin or matriptase, expression and activities of the two serine proteases must be considered at the same time.

REPORTABLE OUTCOMES:

- Manuscripts:

  o Netzel-Arnett S. Currie BM. Szabo R. Lin CY. Chen LM. Chai KX. Antalis TM. Bugge TH. List K. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J. Biol. Chem. 3;281(44):32941-5, 2006

- Meeting presentations:

  o Chen LM, Chai, KX. Prostasin is a metastasis suppressor, actions and mechanisms. In *Era of Hope*, Department of Defense Breast Cancer Research Program Annual Meeting, June 8-11, 2005, Philadelphia, PA.

- Grant applications:

  o Susan G. Komen Breast Cancer Foundation Research Grant (05/01/2007-04/30/2010): Novel Regulators of EGFR Signaling in Breast Cancer. (pending)

- Cell lines generated:

  o The Flp-In T-REx cell lines for single-site chromosome integration and tetracycline-regulated (tet-on) expression of genes of interest, for MDA-MB-231 and MDA-MB-435.

CONCLUSION:

There are several extracellular membrane serine proteases, some are type II transmembrane proteins and some GPI-anchored, associated with cancer and breast cancer phenotypes, such as hepsin (10), matriptase (7), testisin (11), and prostasin (1). Mechanistically it was not clear whether these serine proteases acted alone or in any coordinated way to regulate cell signaling. We had presumed that prostasin re-expression alone in breast cancer cells was adequate for restoring its full biological impact. We have found, however, that at least for this GPI-anchored serine protease, an activation enzyme was required for its biological function. This activation role can be served by matriptase, but may also be served by similar enzymes. The "so what" lesson from the completion of this project is that the membrane serine proteases discovered to

date are not simply "good" (such as testisin or prostasin) or "bad" serine proteases (such as hepsin or matriptase) when they are evaluated for a role in cancer or breast cancer biology. Take for example the previous controvertible findings on matriptase's use as a diagnostic or prognostic marker for breast cancer, the inconsistency in these findings may be a result of not evaluating for its downstream effector serine protease prostasin at the same time. Ultimately the goal of research on the proteases in breast cancer is to use them as markers or as targets for drugs, and the significance of the findings in this project is that all of these potentially interacting and networking enzymes needed to be looked at together.

REFERENCES:

1. Chen LM. Chai KX. Prostasin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation. Int. J. Cancer. 97(3):323-9, 2002

2. Hejnar J, Hajkova P, Plachy J, Elleder D, Stepanets V, Svoboda J. CpG island protects Rous sarcoma virus-derived vectors integrated into nonpermissive cells from DNA methylation and transcriptional suppression. Proc. Natl. Acad. Sci. U S A. 16;98(2):565-9, 2001

3. Meng Q, Xu J, Goldberg ID, Rosen EM, Greenwald RA, Fan S. Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells. Clin. Exp. Metastasis 18(2):139-46, 2000

4. Netzel-Arnett S. Currie BM. Szabo R. Lin CY. Chen LM. Chai KX. Antalis TM. Bugge TH. List K. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J. Biol. Chem. 281(44):32941-5, 2006

5. Chen LM. Skinner ML. Kauffman SW. Chao J. Chao L. Thaler CD. Chai KX. Prostasin is a glycosylphosphatidylinositol-anchored active serine protease. J. Biol. Chem. 276(24):21434-42, 2001

6. Chen LM. Zhang X. Chai KX. Regulation of prostasin expression and function in the prostate. Prostate 59(1):1-12, 2004

7. List K, Bugge TH, Szabo R. Matriptase: potent proteolysis on the cell surface. Mol. Med. 12(1-3):1-7, 2006

8. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 158(4):1301-11, 2001

9. Chen LM. Wang C. Chen MQ. Marcello MR. Chao J. Chao L. Chai KX. Prostasin attenuates inducible nitric oxide synthase expression in lipopolysaccharide-induced urinary bladder inflammation. Am. J. Physiol. – Renal Physiol. 291(3):F567-77, 2006

10. Vasioukhin V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 3(11):1394-7, 2004

11. Tang T, Kmet M, Corral L, Vartanian S, Tobler A, Papkoff J. Testisin, a glycosyl-phosphatidylinositol-linked serine protease, promotes malignant transformation in vitro and in vivo. Cancer Res. 65(3):868-78, 2005

APPENDICES:

Netzel-Arnett S. Currie BM. Szabo R. Lin CY. Chen LM. Chai KX. Antalis TM. Bugge TH. List K. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J. Biol. Chem. 281(44):32941-5, 2006

SUPPORTING DATA: N/A

Evidence for a Matriptase-Prostasin Proteolytic Cascade Regulating Terminal Epidermal Differentiation*

Sarah Netzel-Arnett[‡1], **Brooke M. Currie**[§1], **Roman Szabo**[§],
Chen-Yong Lin[¶], **Li-Mei Chen**[∥], **Karl X. Chai**[∥], **Toni M. Antalis**[‡],
Thomas H. Bugge[§2], and **Karin List**[§]

From the ‡Center for Vascular and Inflammatory Diseases and Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, the §Proteases and Tissue Remodeling Unit, NIDCR, National Institutes of Health, Bethesda, Maryland 20892, the ¶Lombardi Cancer Center, Georgetown University Medical Center, Washington, D. C. 20007, and the ∥Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida 32816-2364

Recent gene ablation studies in mice have shown that matriptase, a type II transmembrane serine protease, and prostasin, a glycosylphosphatidylinositol-anchored membrane serine protease, are both required for processing of the epidermis-specific polyprotein, profilaggrin, stratum corneum formation, and acquisition of epidermal barrier function. Here we present evidence that matriptase acts upstream of prostasin in a zymogen activation cascade that regulates terminal epidermal differentiation and is required for prostasin zymogen activation. Enzymatic gene trapping of matriptase combined with prostasin immunohistochemistry revealed that matriptase was co-localized with prostasin in transitional layer cells of the epidermis and that the developmental onset of expression of the two membrane proteases was coordinated and correlated with acquisition of epidermal barrier function. Purified soluble matriptase efficiently converted soluble prostasin zymogen to an active two-chain form that formed SDS-stable complexes with the serpin protease nexin-1. Whereas two forms of prostasin with molecular weights corresponding to the prostasin zymogen and active prostasin were present in wild type epidermis, prostasin was exclusively found in the zymogen form in matriptase-deficient epidermis. These data suggest that matriptase, an autoactivating protease, acts upstream from prostasin to initiate a zymogen cascade that is essential for epidermal differentiation.

The serine proteases constitute one of the largest classes of proteolytic enzymes and have evolved to perform specialized functions. Trypsin-like serine proteases typically are synthesized as inactive zymogens that are activated by a single endoproteolytic cleavage. This group of enzymes often acts in either single or complex, highly regulated zymogen cascades to control important biological processes such as coagulation, fibrinolysis, blood pressure, and digestion (1–4).

The stratum corneum is the outermost, terminally differentiated layer of the epidermis that provides a physical barrier protecting the body from fluid loss, as well as from mechanical, chemical, and microbial insults. The stratum corneum is a two-compartment structure consisting of a lipid-enriched extracellular matrix in which an interlocking meshwork of flattened dead keratinocytes (corneocytes) are embedded (5–7). Our previous studies have shown that the targeted deletion of the type II transmembrane trypsin-like serine protease, matriptase, leads to loss of inwards and outwards epidermal barrier function due to incomplete corneocyte differentiation and abnormal intercorneocyte lipid extrusion correlating at the molecular level with defective proteolytic processing of profilaggrin (8–11). Interestingly, mice with the targeted deletion of the glycosylphosphatidylinositol (GPI)[3]-anchored trypsin-like serine protease, prostasin (PRSS8), in keratinized tissues recently were reported to display the identical spectrum of deficiencies in stratum corneum formation (12) to those described for matriptase-deficient mice (summarized in Table 1). Moreover, both protease-deficient transgenic mouse strains displayed identical hair follicle defects and thymic abnormalities (Table 1).

The identical phenotypes of matriptase- and prostasin-deficient mice suggested that the two membrane serine proteases either could be components of two distinct zymogen cascades that each are critical to terminal epidermal differentiation or, alternatively, could be components of the same proteolytic cascade. Here we present histological, biochemical, and genetic evidence that matriptase and prostasin define a single zymogen activation cascade in the epidermis, that matriptase acts upstream of prostasin, and that matriptase is an essential epidermal activator of the prostasin zymogen.

EXPERIMENTAL PROCEDURES

Mice—Experiments followed institutional guidelines. Matriptase knock-out and β-galactosidase-tagged matriptase knock-in mice were described (8, 11).

Histological Stains—X-gal and immunohistochemical stains were performed as described (11). The mouse prostasin antibody has been described (13).

Generation of Soluble Recombinant Prostasin—HEK-293T cells were transfected with pCMV-SPORT6 expression vector containing full-length mouse prostasin (I.M.A.G.E clone

[3] The abbreviations used are: GPI, glycosylphosphatidylinositol; PN-1, protease nexin-1; X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside; PI-PLC, phosphatidylinositol-specific phospholipase C.

3600399) or full-length human prostasin cDNA (I.M.A.G.E clone 3138532) in pIRES2-EGFP (Clontech Laboratories, Mountain View, CA) using Polyfect reagent (Qiagen Inc., Valencia, CA). Cells were lysed 24–48 h after transfection using 50 mM Tris, pH 8.0, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40 with protease inhibitor mixture (Sigma). For phosphatidylinositol-specific phospholipase C (PI-PLC) treatment, washed cells were mechanically lifted from the plates by gentle pipetting, incubated with 1 unit/ml PI-PLC (Sigma) in phosphate-buffered saline for 4 h at 4 °C, and centrifuged for 10 min at $1000 \times g$, and the supernatant containing the PI-PLC-released proteins was collected. Protein concentrations were determined with a BCA protein assay Kit (Pierce). The concentration of PI-PLC-released prostasin was estimated by Western blot by serial dilution against a known concentration of activated prostasin obtained commercially.

Prostasin Zymogen Activation by Matriptase—Human soluble prostasin ($\sim$0.1 μM) was incubated with 1 or 10 nM recombinant active human matriptase serine protease domain (14) for 1 h at 37 °C in 50 mM Tris, pH 8.5, 100 nM NaCl. For complex formation, protease nexin-1 (PN-1), 700 mM PN-1 (R&D Systems, Minneapolis, MN) was added for 1 h at 37 °C. Proteins were analyzed by 4–12% reducing SDS-PAGE and Western blotting using a monoclonal anti-prostasin antibody (Pharmingen) and SuperSignal West Dura extended duration kit (Pierce).

Biochemical Analysis of Mouse Epidermis—Epidermis was isolated from newborn mice as described (9), ground into a fine powder in liquid nitrogen, homogenized in ice-cold lysis buffer (50 mM Tris at pH 7.4, 2 mM EDTA, 150 mM NaCl, 1% Nonidet P-40, 0.5% Triton X-100, 0.1% SDS) with protease inhibitor mixture set III (Calbiochem), cleared by centrifugation at $13,000 \times g$ for 20 min at 4 °C, and protein concentration determined by the Bio-Rad protein assay (Bio-Rad). Proteins were resolved by 13% reducing SDS-PAGE and analyzed by Western blot using the monoclonal anti-prostasin antibody described above. Densitometric scanning of Western blots was performed using NIH Image software.

Real-time PCR—RNA was isolated from skin as described (8). The prostasin primers 5′-GGAGGCAAGGATGCCTGCC-A-3′ and 5′-GAGAGTGGGCCCCCAGAGTCAC-3′ were used for quantitative real-time PCR. Prostasin expression levels were normalized against GAPDH mRNA levels in each sample, amplified with the primers 5′-GTGAAGCAGGCATCTGAG-G-3′ and 5′-CATCGAAGGTGGAAGAGTGG-3′.

RESULTS AND DISCUSSION

Co-localization and Coordinated Expression of Matriptase and Prostasin during Terminal Epidermal Differentiation—To analyze expression of matriptase and prostasin in mouse epidermis, we used a knock-in mouse (11) that carries one wild type *matriptase* allele and one allele where the exons encoding the serine protease domain of matriptase have been replaced by a β-galactosidase marker gene (matriptase$^{+/E16\beta\text{-gal}}$ mice). This mouse strain synthesizes a matriptase-β-galactosidase fusion protein under transcriptional control of the endogenous *matriptase* gene and can be used as a sensitive marker for matriptase expression using X-gal staining. The co-localization

of matriptase with prostasin was analyzed by immunohistochemistry of serial sections or, when staining intensity permitted, by immunohistochemical staining of X-gal-stained sections with prostasin antibodies to simultaneously visualize the two proteases. As described recently (11), X-gal staining of the skin of matriptase$^{+/E16\beta\text{-gal}}$ mice showed that matriptase expression was confined to the uppermost living layer of the interfollicular epidermis of 7-day-old mouse pups (Fig. 1A). Interestingly, immunohistochemical staining of interfollicular epidermis revealed a similar localization of prostasin (Fig. 1B). Combined X-gal staining for matriptase and immunohistochemical staining for prostasin revealed overlapping expression in interfollicular epidermis at this age (Fig. 1C) as well as in newborn pups (Fig. 1E), demonstrating that the two membrane-associated proteases have the potential to physically interact *in vivo*. To determine the time of onset of expression of matriptase and prostasin in the developing epidermis, combined X-gal staining and immunohistochemistry of matriptase$^{+/E16\beta\text{-gal}}$ embryos at embryonic day (E) 14.5 to E16.5 was performed. At E14.5 and E15.5 no expression of either of the two serine proteases could be detected (Fig. 1, F and G). At E16.5, however, both matriptase and prostasin were expressed (Fig. 1H), temporally correlating with stratum corneum formation and the onset of acquisition of the epidermal barrier (15). X-gal staining combined with immunohistochemical staining for the marker of basal keratinocytes, cytokeratin-14, demonstrated the clear suprabasal expression of the two proteases at this developmental stage (Fig. 1I).

Matriptase Activates the Prostasin Zymogen in a Cell-free System—Previous studies have shown that the matriptase zymogen undergoes autoactivation during synthesis (16, 17). In contrast, the prostasin zymogen is unable to undergo autoactivation and a physiological activator of prostasin has not been identified (18). Activation of the prostasin zymogen occurs by endoproteolytic cleavage after Arg^{12} within the amino acid sequence QPR^{12}-ITG, a cleavage reaction that could be mediated by matriptase, based on studies of matriptase specificity (19). These observations suggested that matriptase would act upstream of prostasin if the two proteases were part of the same zymogen cascade. To test this, we expressed prostasin in HEK-293T cells. The recombinant prostasin was released from the cell surface with PI-PLC to generate a soluble form of prostasin that presented as a dominant 40-kDa species and two minor species with slightly higher and lower electrophoretic mobility when analyzed by SDS-PAGE and Western blotting under reducing conditions (Fig. 2, *lane 1*). Prostasin generated this way appeared to be predominantly in the zymogen form, as it did not form complexes with the cognate serpin PN-1, which forms SDS-stable complexes with active prostasin (13) but not with the prostasin zymogen (Fig. 2, compare *lane 2* with *lanes 4* and *6*). This suggested that the faint higher and lower molecular weight species both could represent glycosylation variants of the zymogen (13). Activation of the prostasin zymogen leads to the formation of active two-chain prostasin, which can be distinguished from the prostasin zymogen by a small increase in electrophoretic mobility in high-percentage SDS-PAGE gels after reduction of the single disulfide bridge that links the two chains (13). Exposure of soluble prostasin zymogen to either 1

FIGURE 1. **Matriptase and prostasin co-localize and are coordinately expressed in mouse epidermis.** X-gal staining (*A*), prostasin immunohisto-chemistry (*B*), combined X-gal staining and prostasin immunohistochemistry (*C–H*), and combined X-gal staining and cytokeratin-14 (*K14*) immunohis-tochemistry (*I*) of the epidermis of matriptase$^{+/E16\beta\text{-gal}}$ mice (*A, C* and *E–I*) of 7-day-old (*A–D*) or newborn (*E*) pups, or E14.5 (*F*), E15.5 (*G*), and E16.5 embryos (*H* and *I*). Matriptase (*cyan*, examples with *arrows* in *A, C, E, H*, and *I*) and prostasin (*brown*, examples with *arrowheads* in *B, C, E*, and *H*) are co-expressed in the uppermost terminally differentiating layer of the epidermis of 7-day-old (*C*) and newborn (*E*) mice. No expression of either membrane-associated protease is observed at E14.5 (*F*) or E15.5 (*G*), but both matriptase (*cyan*, examples with *arrows*) and prostasin (*brown*, examples with *arrowheads*) are expressed in the developing epidermis at E16.5 (*H*), located in suprabasal keratinocytes (*I*), as revealed by combined X-gal staining for matriptase (*cyan* examples with *arrowheads*) and cytokeratin-14 staining (*brown*, examples with *open arrowheads*). Sections were counterstained with hematoxylin to visualize nuclei. *Size bars*: *A–D* and *F–I*, 20 μm. *E*, 10 μm.


FIGURE 2. **Matriptase converts prostasin zymogen to active prostasin.** Human prostasin zymogen was expressed in HEK-293T cells and released from the surface of cells by hydrolysis of the GPI anchor with PI-PLC. Soluble prostasin zymogen ($\sim$0.1 μM) was incubated for 1 h at 37 °C with buffer (*lanes 1* and *2*), 1 nM (*lanes 3* and *4*), or 10 nM (*lanes 5* and *6*) soluble active human matriptase. At the end of the incubation, buffer (*lanes 1, 3*, and *5*) or 700 nM PN-1 (*lanes 2, 4*, and *6*) was added for 1 h a 37 °C. Proteins were analyzed by SDS-PAGE under reducing conditions, followed by Western blot with a mono-clonal prostasin antibody. The positions of the prostasin zymogen, activated prostasin, and prostasin-PN-1 complexes are indicated. The positions of molecular mass markers (kDa) are indicated on the *left*.

or 10 nM active matriptase protease domain led to the for-mation of a prominent immunoreactive band with the mobility expected for active prostasin (Fig. 2, compare *lane 1*

with *lanes 3* and *5*). The percentage of prostasin zymogen converted to this higher mobility species by matriptase var-ied between prostasin preparations and was never complete, even with very high matriptase concentrations (data not shown). This suggested that not all recombinant prostasin released from HEK-293T cells by PI-PLC was in a conforma-tional state that permitted the activation by matriptase. To confirm that the cleavage of the prostasin zymogen by matriptase leads to the formation of active prostasin, we incubated untreated and matriptase-treated prostasin with PN-1 and detected prostasin-PN-1 complexes by Western blotting using anti-prostasin antibodies. In the absence of preincubation with matriptase, no prostasin-PN-1 complex was observed (Fig. 2, *lane 2*). However, when prostasin zymogen was first exposed to matriptase and then incubated with PN-1, a prominent 85-kDa molecular mass complex that was immunoreactive with anti-prostasin antibodies was observed (Fig. 2, compare *lane 2* with *lanes 4* and *6*). Taken together, these data show that the matriptase catalytic domain is capable of converting the zymogen of prostasin to active, serpin-reactive prostasin in a cell-free system.

Lack of Proteolytically Processed Prostasin Zymogen and Prostasin Zymogen Accumulation in Matriptase-ablated Epidermis—The striking phenotypic similarities between matriptase- and prostasin-deficient mice (Table 1), when combined with our data presented above, strongly suggested that matriptase could be a physiological activator of the prostasin zymogen during terminal epidermal differentiation and predicted the existence of a matriptase-prostasin zymogen cascade in epidermal differentiation. To definitively test this, we determined the state of activation of epidermal prostasin in the presence and absence of matriptase. Protein lysates were prepared from the epidermis of newborn wild type mice and their matriptase-deficient littermates (8), and prostasin processing was analyzed by the separation of the protein lysates by reducing SDS/PAGE on high percentage gradient gels, followed by Western blotting using prostasin antibodies (Fig. 3*A*). In wild type epidermis, prostasin was found in two forms: a 39-kDa form, compatible with the apparent molecular mass of the prostasin zymogen, and a 37-kDa form, compatible with activated prostasin (Fig. 3, *lanes 3–5*). In contrast, in matriptase-ablated epidermis, prostasin was exclusively found in the higher molecular mass 39-kDa zymogen form. Furthermore, the 39-kDa

form of prostasin was frequently more abundant in matriptase-deficient epidermis (Fig. 3, *lanes 6–8*, and data not shown). This increase in prostasin zymogen did not appear to be caused by a corresponding increase in the steady state level of prostasin mRNA as judged by real-time PCR analysis (data not shown), suggesting that the accumulation was caused by loss of zymogen activation by matriptase. To quantitatively assess the formation of active prostasin in matriptase-sufficient and -deficient epidermis, protein extracts from the epidermis of five matriptase-sufficient and five matriptase-deficient littermates were analyzed by Western blot. The fraction of total prostasin presenting as active prostasin was determined by densitometric scanning of the blot (Fig. 3*B*). In matriptase-sufficient epidermis, 40–51% of prostasin was in the active two-chain form, while the amount of active prostasin in matriptase-deficient epidermis was below the level of detection. Taken together, these data provide definitive evidence that matriptase is essential for the proteolytic processing of prostasin in the epidermis.

The coordinated expression and co-localization of matriptase and prostasin in the epidermis and the activation of prostasin zymogen by matriptase *in vitro* and *in vivo*, when combined with the identical phenotype of matriptase and prostasin-deficient mice, provides compelling evidence for the existence of a matriptase-prostasin zymogen activation cascade regulating terminal epidermal differentiation. This suggests that loss of profilaggrin processing, defective corneocyte maturation, and abnormal intercorneocyte lipid extrusion in matriptase-deficient epidermis may all be secondary to loss of prostasin zymogen activation. Increasing evidence indicates that terminal epidermal differentiation is regulated by a sophisticated cascade of serine proteases and serine protease inhibitors that all become expressed in transitional layer cells during stratum corneum formation and undergo sequential activation during stratum corneum maturation and shedding (8, 11, 20–29). The serine proteases currently proposed to be critical for stratum corneum formation include matriptase, prostasin, stratum corneum tryptic enzyme, stratum corneum chymotryptic enzyme, furin, and profilaggrin processing endopeptidase1. Additionally, serine protease inhibitors, including the Kunitz-type serine protease inhibitor, hepatocyte growth factor

TABLE 1

Phenotypic comparison of matriptase and prostasin-deficient mice

Data were compiled from Refs. 8, 9, and 12.

| Parameter	Matriptase−/−	Prostasin−/−
Survival	Postnatal lethality	Postnatal lethality
Body weight and body length	Reduced	Reduced
External appearance of skin	Reddish and wrinkled	Reddish and wrinkled
Hair follicles	Immature	Immature
Thymus	Hypoplastic	Hypoplastic
Inwards epidermal barrier function	Impaired	Impaired
Outwards epidermal barrier function	Impaired	Impaired
Corneocytes	Enlarged	Enlarged
Epidermal lipid composition	Abnormal	Abnormal
Filaggrin	Absent	Absent
Profilaggrin processing	Impaired	Impaired
Epidermal differentiation markers besides profilaggrin/filaggrin	Normal	Normal

FIGURE 3. **Matriptase is required for prostasin activation in mouse epidermis.** *A*, protein lysates were prepared from the epidermis of three newborn matriptase-sufficient (*lanes 3–5*) and three matriptase-deficient littermate mice (*lanes 6–8*) and subjected to SDS-PAGE under reducing conditions followed by Western blot using a mouse monoclonal anti-prostasin antibody. *Lanes 1* and *2* are lysates of concentrated conditioned medium from PI-PLC-treated HEK-293T cells transfected with a mouse prostasin expression plasmid (*PI-PLC*) and cell lysate from mouse prostasin-transfected HEK-293T cells (*Cell lysate*), respectively. The positions of the prostasin zymogen and active prostasin are indicated. The positions of mouse IgG heavy chain and light chain, which are recognized by the secondary antibody, are also indicated. The position of the molecular mass markers (kDa) is indicated on the *left*. *B*, quantitative analysis of prostasin zymogen activation. Epidermal lysates from five newborn matriptase-sufficient and five matriptase-deficient littermate mice were subjected to SDS-PAGE and Western blotting. The fraction of active prostasin as a function of total prostasin in each epidermal lysate was estimated by densitometric scanning of the blot. Error bars indicate standard deviation. $p < 0.008$, Wilcoxon rank-sum test, two-tailed.

activator inhibitor-1, and the Kazal-type, multidomain serine protease inhibitor, SPINK5, could have key roles in regulating the activity of one or several of these proteases in both human and mouse epidermis. Pertubations causing increased or decreased serine protease activity in the upper epidermis have serious pathophysiological consequences. Thus, ablation of matriptase or prostasin prevents acquisition of the epidermal barrier by blocking terminal epidermal differentiation (9, 12), while, conversely, SPINK5 deficiency or overexpression of stratum corneum chymotryptic enzyme compromises the epidermal barrier through premature epidermal differentiation and accelerated shedding of the stratum corneum (21–23, 26). It remains to be determined whether a single proteolytic cascade or multiple independent proteolytic cascades are operational during terminal epidermal differentiation. Previously, stratum corneum tryptic enzyme has been proposed to act upstream of stratum corneum chymotryptic enzyme during the desquamation of stratum corneum (25), and our results now show that matriptase acts upstream of prostasin during terminal epidermal differentiation. In addition to loss of epidermal barrier formation, matriptase deficiency also severely impairs stratum corneum desquamation (9). These observations suggest the intriguing hypothesis that the four serine proteases and SPINK5 could be part of a single zymogen cascade with a complexity reminiscent of other serine protease zymogen cascades, such as those involved in blood coagulation or digestion.

Matriptase and prostasin both have a fairly wide expression in epithelial tissues and both are frequently dysregulated in epithelial tumors (10, 30–43). The role of matriptase as a prostasin zymogen activator and the potential function of the matriptase-prostasin cascade in other physiological processes and in pathophysiological processes, such as cancer, are clearly important areas for future study.

REFERENCES

1. Davie, E. W., Fujikawa, K., and Kiesel, W. (1991). *Biochemistry* **30,** 10363–10370
2. Danø, K., Andreasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. (1985) *Adv. Cancer Res.* **44,** 139–266
3. Kitamoto, Y., Yuan, X., Wu, Q., McCourt, D. W., and Sadler, J. E. (1994) *Proc. Natl. Acad. Sci. U. S. A.* **91,** 7588–7592
4. Rawlings, N. D., Morton, F. R., and Barrett, A. J. (2006) *Nucleic Acids Res.* **34,** D270–D272
5. Nemes, Z., and Steinert, P. M. (1999) *Exp. Mol. Med.* **31,** 5–19
6. Roop, D. (1995) *Science* **267,** 474–475
7. Presland, R. B., and Dale, B. A. (2000) *Crit. Rev. Oral Biol. Med.* **11,** 383–408
8. List, K., Haudenschild, C. C., Szabo, R., Chen, W., Wahl, S. M., Swaim, W., Engelholm, L. H., Behrendt, N., and Bugge, T. H. (2002) *Oncogene* **21,** 3765–3779
9. List, K., Szabo, R., Wertz, P. W., Segre, J., Haudenschild, C. C., Kim, S. Y., and Bugge, T. H. (2003) *J. Cell Biol.* **163,** 901–910
10. List, K., Bugge, T. H., and Szabo, R. (2006) *Mol. Med.* **12,** 1–7
11. List, K., Szabo, R., Molinolo, A., Nielsen, B. S., and Bugge, T. H. (2006) *Am. J. Pathol.* **168,** 1513–1525
12. Leyvraz, C., Charles, R. P., Rubera, I., Guitard, M., Rotman, S., Breiden, B., Sandhoff, K., and Hummler, E. (2005) *J. Cell Biol.* **170,** 487–496
13. Chen, L. Wang, C., Chen, M., Marcello, M. R., Chao, J., Chao, L., and Chai, K. X. (2006) *Am. J. Physiol.* **291,** F567–F577
14. Friedrich, R., Fuentes-Prior, P., Ong, E., Coombs, G., Hunter, M., Oehler, R., Pierson, D., Gonzalez, R., Huber, R., Bode, W., and Madison, E. L. (2002) *J. Biol. Chem.* **277,** 2160–2168
15. Hardman, M. J., Sisi, P., Banbury, D. N., and Byrne, C. (1998) *Development* (*Camb.*) **125,** 1541–1552
16. Oberst, M. D., Chen, L. Y., Kiyomiya, K., Williams, C. A., Lee, M. S., Johnson, M. D., Dickson, R. B., and Lin, C. Y. (2005) *Am. J. Physiol.* **289,** C462–C470
17. Oberst, M. D., Williams, C. A., Dickson, R. B., Johnson, M. D., and Lin, C. Y. (2003) *J. Biol. Chem.* **278,** 26773–26779
18. Shipway, A., Danahay, H., Williams, J. A., Tully, D. C., Backes, B. J., and Harris, J. L. (2004) *Biochem. Biophys. Res. Commun.* **324,** 953–963
19. Takeuchi, T., Harris, J. L., Huang, W., Yan, K. W., Coughlin, S. R., and Craik, C. S. (2000) *J. Biol. Chem.* **275,** 26333–26342
20. Descargues, P., Deraison, C., Bonnart, C., Kreft, M., Kishibe, M., Ishida-Yamamoto, A., Elias, P., Barrandon, Y., Zambruno, G., Sonnenberg, A., and Hovnanian, A. (2005) *Nat. Genet.* **37,** 56–65
21. Yang, T., Liang, D., Koch, P. J., Hohl, D., Kheradmand, F., and Overbeek, P. A. (2004) *Genes Dev.* **18,** 2354–2358
22. Hewett, D. R., Simons, A. L., Mangan, N. E., Jolin, H. E., Green, S. M., Fallon, P. G., and McKenzie, A. N. (2005) *Hum. Mol. Genet.* **14,** 335–346
23. Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A. D., Bonafe, J. L., Wilkinson, J., Taieb, A., Barrandon, Y., Harper, J. I., de Prost, Y., and Hovnanian, A. (2000) *Nat. Genet.* **25,** 141–142
24. Zeeuwen, P. L. (2004) *Eur. J. Cell Biol.* **83,** 761–773
25. Brattsand, M., Stefansson, K., Lundh, C., Haasum, Y., and Egelrud, T. (2005) *J. Invest. Dermatol.* **124,** 198–203
26. Hansson, L., Backman, A., Ny, A., Edlund, M., Ekholm, E., Ekstrand Hammarstrom, B., Tornell, J., Wallbrandt, P., Wennbo, H., and Egelrud, T. (2002) *J. Invest. Dermatol.* **118,** 444–449
27. Resing, K. A., Johnson, R. S., and Walsh, K. A. (1993) *Biochemistry* **32,** 10036–10045
28. Resing, K. A., Thulin, C., Whiting, K., al-Alawi, N., and Mostad, S. (1995) *J. Biol. Chem.* **270,** 28193–28198
29. Pearton, D. J., Nirunsuksiri, W., Rehemtulla, A., Lewis, S. P., Presland, R. B., and Dale, B. A. (2001) *Exp. Dermatol.* **10,** 193–203
30. Oberst, M., Anders, J., Xie, B., Singh, B., Ossandon, M., Johnson, M., Dickson, R. B., and Lin, C. Y. (2001) *Am. J. Pathol.* **158,** 1301–1311
31. Benaud, C., Dickson, R. B., and Lin, C. Y. (2001) *Eur. J. Biochem.* **268,** 1439–1447
32. Benaud, C., Oberst, M., Hobson, J. P., Spiegel, S., Dickson, R. B., and Lin, C. Y. (2002) *J. Biol. Chem.* **277,** 10539–10546
33. Oberst, M. D., Johnson, M. D., Dickson, R. B., Lin, C. Y., Singh, B., Stewart, M., Williams, A., al-Nafussi, A., Smyth, J. F., Gabra, H., and Sellar, G. C. (2002) *Clin. Cancer Res.* **8,** 1101–1107
34. Kang, J. Y., Dolled-Filhart, M., Ocal, I. T., Singh, B., Lin, C. Y., Dickson, R. B., Rimm, D. L., and Camp, R. L. (2003) *Cancer Res.* **63,** 1101–1105
35. Oberst, M. D., Singh, B., Ozdemirli, M., Dickson, R. B., Johnson, M. D., and Lin, C. Y. (2003) *J. Histochem. Cytochem.* **51,** 1017–1025
36. Hoang, C. D., D'Cunha, J., Kratzke, M. G., Casmey, C. E., Frizelle, S. P., Maddaus, M. A., and Kratzke, R. A. (2004) *Chest* **125,** 1843–1852
37. Santin, A. D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J. J., O'Brien, T. J., Tian, E., Cannon, M. J., Shaughnessy, J., Jr., and Pecorelli, S. (2004) *Int. J. Cancer* **112,** 14–25
38. Tanimoto, H., Shigemasa, K., Tian, X., Gu, L., Beard, J. B., Sawasaki, T., and O'Brien, T. J. (2005) *Br. J. Cancer* **92,** 278–283
39. Yu, J. X., Chao, L., and Chao, J. (1995) *J. Biol. Chem.* **270,** 13483–13489
40. Chen, L. M., Hodge, G. B., Guarda, L. A., Welch, J. L., Greenberg, N. M., and Chai, K. X. (2001) *Prostate* **48,** 93–103
41. Mok, S. C., Chao, J., Skates, S., Wong, K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., and Cramer, D. W. (2001) *J. Natl. Cancer Inst.* **93,** 1458–1464
42. Chen, L. M., and Chai, K. X. (2002) *Int. J. Cancer* **97,** 323–329
43. Fukushima, K., Naito, H., Funayama, Y., Yonezawa, H., Haneda, S., Shibata, C., and Sasaki, I. (2004) *J. Gastroenterol.* **39,** 940–947